In summary, we have uncovered a new therapeutic strategy for targeting neutrophil and macrophage infiltration in TACE therapy for HCC via inhibition of the CCL2/CCR2 and CXCLs/CXCR2 axes. Here, CCR2 is linked to hepatocellular carcinoma.